BofA lowered the firm’s price target on Acadia Healthcare (ACHC) to $44.50 from $50 and keeps a Buy rating on the shares. 2025 guidance was below expectations on higher startup losses and Acadia lowered its long-term growth outlook by 200 basis points to 7%-9% revenue growth and EBITDA growth of 8%-10%, notes the analyst, who cut the firm’s 2025 and 2026 EBITDA forecasts in response.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Closing Bell Movers: HP slips 4% as guidance disappoints; Elastic up 15%
- Acadia Healthcare reports Q4 adjusted EPS 64c, consensus 71c
- Acadia Healthcare sees FY25 EPS $2.50-$2.80, consensus $3.36
- Acadia Healthcare sees Q1 revenue $765M-$775M, consensus $822.03M
- Acadia Healthcare’s Strategic Expansion and Earnings Growth Potential Justify Buy Rating